Zejula-Keytruda Combo Shows Promise in Certain Ovarian Cancer Patients in Clinical Trial
News
A combination of Zejula (niraparib) and Keytruda (pembrolizumab) reduced tumor size in one out of four difficult-to-treat ovarian cancer patients, Tesaro‘s Phase 1/2 trial revealed. The 25% response rate seen in ... Read more